Cancer Genetics, Inc. Renamed to Vyant Bio, Inc. Vyant Bio, Inc. will begin trading on Nasdaq under the symbol VYNT CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc...
Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary...
RUTHERFORD, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the βCompanyβ) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment...
RUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the βCompanyβ) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay...
RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the βCompanyβ) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay...
RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the βCompanyβ) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
RUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the βCompanyβ) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the βCompanyβ) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
RUTHERFORD, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the βCompanyβ) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.